Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019641HBVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS10012329HBVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS10021125HBVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS10020263HBVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS10042452HBVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS30000692HIVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS30003749HIVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS30063386HIVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS30063387HIVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TVIS30063388HIVENSG00000133835.18protein_codingHSD17B4NoNo3295A0A0S2Z4J1
P51659
TCGA Plot Options
Drug Information
GeneHSD17B4
DrugBank IDDB00157
Drug NameNADH
Target IDBE0000408
UniProt IDP51659
Regulation Type
PubMed IDs17139284; 17016423; 12517343
CitationsOverington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Haapalainen AM, Koski MK, Qin YM, Hiltunen JK, Glumoff T: Binary structure of the two-domain (3R)-hydroxyacyl-CoA dehydrogenase from rat peroxisomal multifunctional enzyme type 2 at 2.38 A resolution. Structure. 2003 Jan;11(1):87-97.
GroupsApproved; Nutraceutical
Direct Classification(5'->5')-dinucleotides
SMILESNC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O
PathwaysEthylmalonic Encephalopathy; 3-Methylglutaconic Aciduria Type III; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Caffeine Metabolism; Fructose and Mannose Degradation; Isovaleric Aciduria; Lysine Degradation; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Glycerol Phosphate Shuttle; Zellweger Syndrome; Propionic Acidemia; Glycolysis; Xanthine Dehydrogenase Deficiency (Xanthinuria); S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Tryptophan Metabolism; Glutaric Aciduria Type I; 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Glycine N-Methyltransferase Deficiency; Dimethylglycine Dehydrogenase Deficiency; Androgen and Estrogen Metabolism; Nucleotide Sugars Metabolism; 3-Methylglutaconic Aciduria Type IV; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Malate-Aspartate Shuttle; Folate Metabolism; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease; Glycerol Kinase Deficiency; Adenylosuccinate Lyase Deficiency; Cysteine Metabolism
PharmGKBPA164755085
ChEMBLCHEMBL1234616